Moderna Stock Drops Amid Sell Rating and Raised Price Target
Moderna stock plummeted after Rothschild Redburn downgraded its rating to Sell on September 3, 2026.
The firm raised its price target to USD 81 from USD 40, sparking a 2.9 percent drop in shares to USD 146.24 by the end of trading on September 4, 2026.
This move followed a surge after Moderna and Merck reported positive Phase 3 trial data for intismeran autogene, a cancer vaccine candidate.